Follow
Raquel Comas
Raquel Comas
Vall d'Hebron Instituto de Oncología
Verified email at vhio.net
Title
Cited by
Cited by
Year
Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer
G Serna, F Ruiz-Pace, J Hernando, L Alonso, R Fasani, S Landolfi, ...
Annals of Oncology 31 (10), 1366-1375, 2020
842020
Descriptive epidemiology of primary malignant and non-malignant central nervous tumors in Spain: Results from the Girona Cancer Registry (1994–2013)
R Fuentes-Raspall, M Solans, A Roca-Barceló, L Vilardell, M Puigdemont, ...
Cancer epidemiology 50, 1-8, 2017
512017
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer
E Elez, J Ros, J Fernández, G Villacampa, AB Moreno-Cárdenas, ...
Nature medicine 28 (10), 2162-2170, 2022
472022
Integración de herramientas de control de gestión para el alineamiento estratégico en el sistema empresarial cubano. Aplicación en empresas de Sancti Spiritus
R Comas
MSc. Tesis, 2013
242013
Gestión del cambio y Dirección Estratégica
V Vega, R Comas
Quito: El siglo, 2017
222017
Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments
J Ros, J Matito, G Villacampa, R Comas, A Garcia, G Martini, I Baraibar, ...
Annals of Oncology 34 (6), 543-552, 2023
202023
Incidence and survival of Hodgkin lymphoma patients in Girona (Spain) over three decades: a population-based study
M Solans, L Serra, G Renart, G Osca-Gelis, R Comas, L Vilardell, ...
European Journal of Cancer Prevention 26, S164-S169, 2017
122017
La investigación científica y las formas de titulación, aspectos conceptuales y prácticos
A Romero, F Castro, G Álvarez, M Velázquez, R Comas, V Falcon
Ecuador: Universidad Regional Autónoma de los Andes, 2017
112017
LBA-3 Integrated analysis of cell-free DNA (cfDNA) BRAF mutant allele fraction (MAF) and whole exome sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with …
E Élez, J Ros, G Martini, J Matito, G Villacampa, F Salva, I Baraibar, ...
Annals of Oncology 32, S226-S227, 2021
102021
Patient and tumor characteristics as determinants of overall survival (OS) in BRAF V600 mutant (mt) metastatic colorectal cancer (mCRC) treated with doublet or …
J Ros Montañá, G Martini, I Baraibar, G Villacampa, R Comas, ...
Journal of Clinical Oncology 38 (15_suppl), 4112-4112, 2020
102020
Challenges in assessing the real incidence of chronic lymphocytic leukemia: 16 years of epidemiological data from the province of Girona, Spain
M Solans, G Osca-Gelis, R Comas, JM Roncero, D Gallardo, ...
Cancer Causes & Control 29, 379-382, 2018
92018
A Comprehensive Biomarker analysis of microsatellite Unstable/Mismatch repair deficient colorectal Cancer cohort treated with immunotherapy
E Élez, N Mulet-Margalef, M Sanso, F Ruiz-Pace, FM Mancuso, R Comas, ...
International Journal of Molecular Sciences 24 (1), 118, 2022
32022
Young-onset colorectal cancer: A call for action.
I Baraibar, F Salva, R Comas, J Ros, A Garcia, M Sanchis, JL Cuadra, ...
Journal of Clinical Oncology 39 (15_suppl), 10563-10563, 2021
22021
Mortality of women with ductal carcinoma in situ of the breast: A population-based study from the Girona province, Spain (1994–2013)
A Roca-Barceló, G Viñas, H Pla, A Carbó, R Comas, Á Izquierdo, ...
Clinical and Translational Oncology 21, 891-899, 2019
22019
Impact of the COVID-19 pandemic in the early-onset colorectal cancer
I Baraibar, A García, F Salvà, J Ros, N Saoudi, R Comas, G Castillo, ...
Translational Oncology 32, 101668, 2023
12023
426P Spotlight on refractory metastatic colorectal cancer (refMCRC): Role of prognostic characteristics in the continuum of care
AA Valdivia, F Salva, J Ros, I Baraibar, GA Martinez, NS Gonzalez, ...
Annals of Oncology 32, S547-S548, 2021
12021
445P Tumor load surrogates as major prognostic factors in BRAF-V600E mutated (mt) colorectal (CRC) patients treated with BRAF inhibitor+ antiEGFR+/-MEK inhibitor
FJR Montana, G Martini, GV Javierre, I Baraibar, R Comas, A Garcia, ...
Annals of Oncology 32, S556, 2021
12021
461P Molecular tumor profiling and matched molecular targeted treatment in metastatic young-onset colorectal cancer (YOCR)
IB Argota, J Ros, R Comas, S Aguilar, F Salva, A Garcia, JLC Urteaga, ...
Annals of Oncology 32, S562-S563, 2021
12021
Mucinous differentiation (MD) as predictor of response in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with BRAF inhibitors (BRAFi) combinations
FJ Ros Montana, V Navarro, R Comas, S Landolfi, L Ramirez, HG Palmer, ...
ANNALS OF ONCOLOGY 34, S447-S447, 2023
2023
626P Mucinous differentiation (MD) as predictor of response in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with BRAF inhibitors (BRAFi) combinations
FJR Montana, V Navarro, R Comas, S Landolfi, L Ramirez, HG Palmer, ...
Annals of Oncology 34, S447, 2023
2023
The system can't perform the operation now. Try again later.
Articles 1–20